Over at Linked In, David Crean provides highlights of the January 2026 Silicon Valley Bank life science investment report. Providing links to a 29-page Silicon Valley Bank investment report, of $46B healthcare investment in 2025, $22B or 46% was healthcare AI. Diagnostics/tools, biopharma, and devices were down and flat.
- Find Crean here.
- Find his Substack blog here.
- Find the current article here.
- Find the SVB report there or here.
Here are some quotes:
Strip out AI-related deals, and the rest of the market is in sharp contraction:
- Biopharma: $21.6B (-19% YoY from $26.6B)
- Healthtech: $13.8B (+5% YoY from $13.2B, AI-driven)
- Dx/Tools: $4.3B (-35% YoY from $6.6B)
- Device: $6.9B (flat YoY from $6.8B)
AI: When One Theme Consumes Half a Market
Healthcare AI is projected to reach $22B which equates to 46% of total healthcare VC.
##
See his article, VC is Broken.
 |
| cllick to enlarge |
x
Chat GPT 5.3 summarizes.
The Silicon Valley Bank Healthcare Investments and Exits H1 2026 report describes a venture ecosystem that has split into two distinct worlds: a booming AI-driven segment and a broader healthcare investment market that remains constrained by tighter capital and fewer exits.
Venture fundraising for healthcare has fallen sharply from its pandemic-era peak. Healthcare-focused venture funds raised only about $6.9B in 2025, compared with $41B in 2021, reflecting limited partner caution as IPO and acquisition activity slowed and distributions back to investors declined.
Artificial intelligence now dominates healthcare investment. AI-related companies account for roughly 46% of healthcare venture funding, driven largely by extremely large financing rounds. In particular, deals exceeding $300 million—often tied to generative AI models, drug discovery platforms, or large healthcare data systems—have grown rapidly and now represent a major share of capital deployed. These unusually large rounds have reshaped funding dynamics and concentrated investment among a small number of companies.
Outside AI, the sector increasingly reflects a “haves versus have-nots” environment. Early-stage funding, particularly Series A rounds, remains accessible for strong teams with compelling ideas.
However, later-stage rounds such as Series B and C have become significantly harder to secure unless companies demonstrate clear clinical validation, revenue traction, or other strong fundamentals. Investors are writing fewer checks and concentrating capital in companies with defensible technologies and clear paths to value creation.
Sector trends vary. Biopharma remains the largest destination for investment, although overall funding has declined and investors are favoring validated biological targets and proven drug modalities. Healthtech investment is heavily driven by AI, especially tools that improve provider operations or provide clinical knowledge support. Diagnostics and tools companies face the most pressure due to reimbursement and commercialization challenges. Medical devices have remained comparatively stable, with activity centered on surgical robotics, brain–computer interfaces, and AI-enhanced imaging technologies.
Another emerging theme is longevity and healthspan, spanning geroscience research, consumer health optimization products, and technologies aimed at preserving functional ability in aging populations. Interest from major pharmaceutical companies—particularly around metabolic drugs such as GLP-1 therapies—suggests that this area may become a larger strategic focus.
Overall, healthcare venture investing appears to be resetting after the exuberance of the early 2020s. AI continues to attract large amounts of capital, but across the rest of the sector investors are demanding stronger fundamentals, clearer commercialization strategies, and credible exit pathways before committing funding.
The report portrays diagnostics and research tools (Dx/Tools) as one of the most pressured segments of healthcare venture investment right now. In contrast to AI-heavy healthtech or well-validated biopharma assets, diagnostics sits at the intersection of science risk, reimbursement risk, and commercialization complexity, which makes investors cautious. As a result, the sector experienced a noticeable decline in both deal volume and capital invested during 2025.
Investment contraction.
Total Dx/Tools venture investment fell substantially in 2025 to roughly $4.3B across about 388 deals, down from about $6.6B in 2024. The decline reflects a broad reset in healthcare venture markets: investors are writing fewer checks, raising fewer funds themselves, and concentrating capital in fewer companies with stronger fundamentals. Diagnostics is particularly exposed to this shift because many companies historically raised early rounds based on proof-of-concept science rather than near-term revenue.
Reimbursement and commercialization pressures.
A recurring theme in the report is that diagnostics companies face persistent uncertainty around revenue models and reimbursement pathways. Unlike therapeutics, where regulatory approval can create large value inflection points, diagnostics often depend on payer coverage decisions, clinical adoption, and integration into healthcare workflows. These factors make investors wary of long commercialization timelines and unpredictable pricing dynamics.
Shift toward platforms and data moats.
Despite the overall downturn, the deals that did occur tended to focus on companies with:
AI-driven biology platforms that accelerate drug discovery or biomarker identification
“Picks-and-shovels” infrastructure for research, such as spatial profiling or computational biology tools
Large proprietary datasets that create defensible competitive advantages
Examples highlighted include companies building foundational biological models, spatial biology platforms, or computational design tools that could shorten preclinical and clinical timelines.
Diagnostics evolving toward proactive care.
The report also notes a conceptual shift in diagnostics investment: some companies are positioning diagnostics not just as tests ordered during illness, but as tools for continuous monitoring, patient-initiated screening, and preventive medicine. Investors see potential in diagnostics integrated into consumer health, decentralized care, and early disease detection.
Bottom line.
Diagnostics is currently in a capital-constrained but strategically important phase. The easy funding for proof-of-concept diagnostic ideas has largely disappeared. Investors are instead focusing on companies that combine strong science with clear commercialization paths—especially those with scalable data platforms, AI integration, or the potential to reshape how diagnostics are used in proactive healthcare.
